Health systems + data
Personalized Medicine Loops
A personalized recommendation is only as useful as the governed follow-up system that observes what happens next.
NIH's June 2026 All of Us release made data from more than 747,000 participants available to researchers, including over 535,000 whole-genome sequences linked to nearly 482,000 electronic health records. The scale is extraordinary, but the operating opportunity is not simply more prediction. Health systems need a loop that connects consented data, an evidence-based recommendation, clinician and patient action, follow-up measurement, and a governed record of outcomes.
What changed
Genomic data can now be analyzed alongside electronic health records, surveys, physical measurements, environmental context, and wearable data at population scale. FDA guidance also recognizes real-world data from EHRs, claims, registries, and digital health technologies as potential inputs to real-world evidence. The bottleneck is moving from analytical possibility to a safe, repeatable care workflow.
What leaders should do
Choose a narrow clinical use case with an established evidence base and a defined action pathway. Document who is eligible, which data are required, how missingness is handled, where consent applies, which clinician reviews the recommendation, how uncertainty is communicated, and what follow-up measure closes the loop. Monitor access and performance by patient group to detect unequal reach or benefit.
What ZOAK wants to build
A care-loop orchestration layer for evidence-backed personalized programs. It would coordinate eligibility, consent, testing, decision support, patient communication, follow-up timing, outcome capture, and exception review while keeping clinical authority with licensed teams and preserving a traceable evidence record.
Operating analysis
Precision medicine is often presented as a matching problem: identify the right treatment for the right person. In practice, implementation is a sequence of dependent operational steps. A valid result may never reach the right clinician. A recommendation may arrive without the data needed to interpret it. A patient may begin a plan but miss follow-up. An outcome may be documented in free text and never return to the program's evidence base.
The European Observatory on Health Systems and Policies argues that personalized medicine needs robust regulatory and operational frameworks across the health continuum. That means governance cannot be added after the model or test is selected. Data provenance, consent, access controls, clinical responsibility, reimbursement, patient communication, and outcome measurement are part of the product.
FDA's pharmacogenetic-association table illustrates a further guardrail: genotype can inform therapeutic strategy, dosage, benefit, or toxicity for some drug-gene relationships, but providers must still use FDA-approved labeling and account for other clinical factors. The workflow should therefore present the evidence and its limits, not convert a genetic signal into an autonomous prescribing decision.
| Evidence | What it enables | Required control |
|---|---|---|
| NIH All of Us: 747,000+ participants, 535,000+ whole genomes, and nearly 482,000 linked EHRs | Research across genomic, clinical, behavioral, and environmental factors at unprecedented scale. | Tiered access, privacy safeguards, data-quality review, and careful limits on generalization. |
| FDA: real-world data may come from EHRs, claims, registries, and digital health technologies | Lifecycle evidence about the use, benefits, and risks of medical products. | Fit-for-purpose data, documented methods, and regulatory-quality analysis. |
| FDA: supported pharmacogenetic associations can inform treatment strategy or risk | More precise clinical consideration for defined drug-gene relationships. | Clinician review, approved labeling, patient context, and monitoring. |
What would we build first?
A workflow for one evidence-backed use case at one care site, integrated with existing clinical systems. The first release would manage referral, consent, result routing, clinician acknowledgment, patient communication, scheduled follow-up, and a small outcome set. It would not attempt to make autonomous clinical decisions.
How would success be measured?
Eligible-patient reach, time from eligibility to result, result acknowledgment, time to clinical action, follow-up completion, data completeness, exception rate, patient understanding, and outcome measures appropriate to the specific program. All should be stratified to identify access or performance gaps.
What should the product never hide?
The source and version of the evidence, relevant population, missing data, uncertainty, who reviewed the result, what action was taken, and when follow-up is due. This article describes an operating model, not medical advice or a clinical recommendation.
Sources: NIH All of Us data release, June 2026, FDA Real-World Evidence, FDA Table of Pharmacogenetic Associations, European Observatory policy brief on personalized medicine, 2025
Related engagement
Turning a validated clinical concept into a governed operating workflow?
We can map the decision, consent, follow-up, evidence, and measurement layers with your clinical and compliance teams.
Discuss the operating model